CytomX Therapeutics Inc (NASDAQ:CTMX) Director Frederick W. Gluck sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $25.01, for a total transaction of $250,100.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of CytomX Therapeutics Inc (NASDAQ CTMX) opened at $24.83 on Wednesday. CytomX Therapeutics Inc has a 1-year low of $11.11 and a 1-year high of $25.79. The firm has a market cap of $953.69 and a P/E ratio of -15.82.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.14). CytomX Therapeutics had a negative net margin of 113.64% and a negative return on equity of 92.42%. research analysts expect that CytomX Therapeutics Inc will post -1.58 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of the business. Bank of Montreal Can purchased a new position in CytomX Therapeutics in the 4th quarter valued at approximately $124,000. Algert Global LLC boosted its position in CytomX Therapeutics by 31.8% in the 3rd quarter. Algert Global LLC now owns 45,853 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 11,050 shares during the period. Iguana Healthcare Management LLC boosted its position in CytomX Therapeutics by 16.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 70,000 shares of the biotechnology company’s stock valued at $1,272,000 after buying an additional 10,000 shares during the period. AMP Capital Investors Ltd purchased a new position in CytomX Therapeutics in the 3rd quarter valued at approximately $735,000. Finally, Allianz Asset Management GmbH purchased a new position in CytomX Therapeutics in the 3rd quarter valued at approximately $995,000. 63.13% of the stock is owned by institutional investors.
A number of brokerages have recently issued reports on CTMX. Wedbush set a $37.00 price target on shares of CytomX Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 4th. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Oppenheimer reiterated a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Bank of America lifted their target price on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Finally, Citigroup started coverage on shares of CytomX Therapeutics in a report on Friday, January 5th. They issued a “buy” rating and a $40.00 target price for the company. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. CytomX Therapeutics has a consensus rating of “Buy” and a consensus price target of $32.78.
TRADEMARK VIOLATION WARNING: “Frederick W. Gluck Sells 10,000 Shares of CytomX Therapeutics Inc (NASDAQ:CTMX) Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/17/frederick-w-gluck-sells-10000-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.